HCPCS Level II code J9033 denotes the injectable chemotherapy agent bendamustine hydrochloride, billed per 1 mg unit. As a widely used cytotoxic drug for hematologic malignancies, accurate coding with J9033 affects medication billing, inventory control, and aggregation of chemotherapy utilization data nationally. This code matters to providers, payers, and pharmacy services because it ties drug acquisition, billing units, and site-of-care charges to a standardized HCPCS identifier.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bendamustine use, common sites of service where J9033 is billed, and the types of benchmarks and policy topics typically associated with HCPCS drug codes (unitization, site-of-service considerations, and payer coverage variances). The publication also highlights common modifier usage and practical billing considerations relevant to infusion services.

This national-level summary is intended to help billing managers, pharmacists, and policy analysts understand what J9033 represents, which payers are commonly involved, and what categories of information — including reimbursement benchmarks, policy updates, and clinical context — are covered in the full publication. Data not available in the input.